Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE)

Similar documents
PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB. Patient s first names.

Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth.

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names.

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

Patient's surname/family name. Patient's first names. Date of birth. Responsible health professional. Job title. NHS number (or other identifier)

Patient agreement to investigation or treatment. Emergency Spinal Discectomy/Decompression. Patient details (or pre-printed label)

Patient agreement to investigation or treatment. Spinal Injections. Patient details (or pre-printed label) Patient s surname/family name...

High dose cytarabine (Lymphoma)

Fitting of an Intrauterine Device (IUD)

CONSENT FORM UROLOGICAL SURGERY

Pentostatin (Nipent )

High dose melphalan conditioning for autologous transplant (inpatient) Palatine treatment centre

Bendamustine. Bendamustine. Your treatment Your doctor or nurse clinician has prescribed a course of treatment with bendamustine.

Oral Etoposide (Lymphoma)

Brentuximab vedotin. Brentuximab vedotin

Laparoscopic radical nephrectomy

Abemaciclib (Verzenios ) Abemaciclib (Verzenios )

Percutaneous nephrolithotomy (PCNL)

Fractured neck of femur

Oral cyclophosphamide in ovarian cancer

Canalplasty / excision of exostoses

Paclitaxel (Taxol) and carboplatin

Mitomycin C given by injection into a vein. Cisplatin and hydration (fluids) via a drip over 6 or 18 hours.

Diagnostic and therapeutic pleural aspiration

West Suffolk Hospital

Cisplatin and gemcitabine (GI)

GCVP. Cyclophosphamide by injection Vincristine by short infusion. Gemcitabine by infusion over 30 minutes

Methotrexate. You will have a routine blood test before the start of each cycle of treatment.

ABVD. by infusion over 30 minutes. You will have treatment on Day 1 and Day 15 (this is one cycle) for 2, 3 or 6 cycles.

Gemcitabine and carboplatin (Breast)

Hospital No. Weston Park Hospital contact number

Sorafenib (Nexavar ) For thyroid carcinoma

Cisplatin and radiotherapy to the

Weekly standard dose. Paclitaxel (Taxol) and carboplatin

Treatment FLAG. An information guide

MACE. Etoposide via an infusion (drip) over 1 hour, once a day for 5 days

Doxorubicin & Ifosfamide

Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer)

Epirubicin. Epirubicin

Low dose cytarabine (Low dose Ara C) Cancer Services Information for patients

Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card)

Vinblastine (Lymphoma)

Transperineal ultrasound-guided biopsy of the prostate gland

Pemetrexed (Alimta )

Gemcitabine and Cisplatin (urology)

Department of Clinical Haematology. Chemotherapy. Information for patients. Page 1 of 12

Mastoidectomy or combined approach tympanoplasty

VDC IE. Your treatment You will have 14 cycles of VDC IE given every 2 to 3 weeks.

IVAC IVAC (Lymphoma) 1277 IVAC (Lymphoma) Page 1 of 6

Arthroscopic subacromial decompression (ASD) with or without AC joint removal

ChIVPP. ChIVPP. Day 1 to 14 Chlorambucil tablets Procarbazine capsules Prednisolone tablets

GDP GDP Gemcitabine, Dexamethasone, CisPlatin Your treatment Day 1 Days 1 to 4 Day 8 dexamethasone

Direct Current Cardioversion (DCCV)

Myocet. Myocet. Myocet is given into the vein (intravenously) through a fine tube (cannula) as an infusion over 1 hour.

ABVD. by infusion over 30 minutes. You will have treatment on Day 1 and Day 15 of a 28 day cycle. You will have 2, 3 or 6 cycles.

Bevacizumab (Avastin ) treatment for Neurofibromatosis Type 2 (NF2) Information for patients

Tamoxifen Tamoxifen. Your treatment Your doctor or nurse clinician has prescribed for you a treatment which includes the hormonal therapy tamoxifen.

VIDE. Vincristine given via intravenous (IV) infusion over 10 minutes Etoposide & doxorubicin given together via IV infusion over 4 hours

Gemcitabine and carboplatin (Lung)

Obinutuzumab (lymphoma) Obinutuzumab (lymphoma)

Myeloma Haematology and Transplant Unit CTD1

Paclitaxel (Taxol) Paclitaxel is given into the vein (intravenously) through a fine tube (cannula) as an infusion over 1 hour.

Vinorelbine (Oral) Oral Vinorelbine

DHAP DHAP Your treatment dexamethasone Possible side effects

Capecitabine (Xeloda) tablets

Gemcitabine and carboplatin (Lung)

Myeloma Haematology and Transplant Unit

Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005

Pazopanib (Votrient ) oral for renal tumours

Transcription:

Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number (or other identifier) South London Healthcare NHS Trust: Princess Royal University Hospital Queen Elizabeth Hospital Queen Mary s Hospital Male Female Special requirements (e.g. other language/other communication method) Treatment for Acute Myeloid Leukaemia Intravenous High dose Cytarabine Responsible health professional Job title Name of proposed procedure or course of treatment (include brief explanation if medical term not clear) Cytarabine intravenous chemotherapy twice daily on days 1, 3 and 5 of the cycle. Up to 2 cycles in total may be given at the discretion of the treating doctor. Statement of health professional (to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in consent policy) I have explained the procedure to the patient. In particular, I have explained:

Patient identifier/label: Page 2 of 6 The intended benefits Improved survival Control of symptoms Induction therapy given in acute state of the disease, aiming to reach response and to introduce steady state of the disease Curative to give you the best possible chance of being cured Maintenance therapy given on continuing basis, aiming to prevent disease flaring up and to control the symptoms Disease control/ palliative the aim is not to cure but to control or shrink the disease. The aim is to improve both quality and quantity of life Significant, unavoidable or frequently occurring risks: Common side-effects include bruising or bleeding, anaemia (low number of red blood cells), feeling sick (nausea) and being sick (vomiting), diarrhoea, loss of appetite, sore mouth and ulcers, and taste changes. Cytarabine may cause an inflammation of the lining of the eyelids (conjunctiva) that makes your eyes feel sore, red and itchy (conjunctivitis). You will get steroid eye drops during and for 3 days following the chemotherapy to prevent this. Less common but potentially life threatening side-effects include reduced resistance to infection which can lead to a blood infection. Contact your doctor or the hospital straight away if: your temperature goes above 38ºC (100.4ºF) you suddenly feel unwell (even with a normal temperature). There may be increased risk of tumour-lysis syndrome in the presence of high tumour burden (high number of cancer cells present in the body). This means symptoms caused by the breakdown of cells initiated by the treatment. High risk patients will be prescribed preventative supplementary medicines Reduced immune function can activate underlying infections. You will be given preventative antimicrobial medication (.........) during your treatment to reduce risk of infections whilst your immune system is affected.

Patient identifier/label: Page 3 of 6 Other less common side-effects include hair thinning and very rarely hair loss, liver changes, lung changes (tell your doctor if you have cough or feel breathless), flulike symptoms, fatigue, skin changes and sore hands and feet. High-dose treatment can cause temporary or occasionally permanent changes to the nervous system. This may cause a variety of symptoms, including seizures (fits), drowsiness, unsteadiness and mood changes. Tell your doctor right away if you have any of these symptoms: lack of energy (lethargy), sleepiness, confusion or loss of balance. Tell to the nurse administering the treatment if you feel any pain during the infusion is being given. Cancer can increase your risk of developing a blood clot (thrombosis), and having chemotherapy may increase this risk further. A blood clot may cause pain, redness and swelling in a leg, or breathlessness and chest pain - you must tell your doctor straight away if you have any of these symptoms. Some chemotherapy drugs can damage women s ovaries and men s sperm, with risk of infertility and early menopause in women. I have warned the patient about the likelihood of: early menopause in women infertility (in men and in women) Some chemotherapy drugs may damage the development of a baby in the womb (foetus), leading to the many risks associated with an abnormal pregnancy. Therefore, I have discussed the issues of protected sex. This is an issue for both men and women. The patient has been advised not to become pregnant / not to get a partner pregnant during the period of treatment. What the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, follow-up appointments etc) and location. Any other risks:... I have also discussed what the procedure is likely to involve, the benefits and risks of any available alternative treatments (including no treatment) and any particular concerns of this patient. The following leaflet/tape has been provided: Macmillan/Cancerbackup leaflet for Cytarabine 24 hour chemotherapy service contact details..

Patient identifier/label: Page 4 of 6 Signed:. Name (PRINT). Date.... Job title... Contact details (if patient wishes to discuss options later)... Statement of interpreter (where appropriate) Language Line ref: I have interpreted the information above to the patient to the best of my ability and in a way in which I believe s/he can understand. Signed.. Date... Name (PRINT).. Copy accepted by patient: yes/no (please ring)

Patient identifier/label: Page 5 of 6 Statement of patient Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of page 2 which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask we are here to help you. You have the right to change your mind at any time, including after you have signed this form. I agree to the procedure and course of treatment described on this form. I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate training and experience. I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health. I have been told about additional procedures which may become necessary during my treatment. I have listed below any procedures which I do not wish to be carried out without further discussion. Patient s signature.. Date.. Name (PRINT) A witness should sign below if the patient is unable to sign but has indicated his or her consent. Young people/children may also like a parent to sign here (see notes). Signature Date... Name (PRINT). Confirmation of consent (to be completed by a health professional when the patient is admitted for the procedure, if the patient has signed the form in advance) On behalf of the team treating the patient, I have confirmed with the patient that s/he has no further questions and wishes the procedure to go ahead. Signed:. Name (PRINT). Date.... Job title... Important notes: (tick if applicable) See also advance decision (eg Jehovah s Witness form) Patient has withdrawn consent (ask patient to sign /date here)....

Patient identifier/label: Page 6 of 6 Guidance to health professionals (to be read in conjunction with consent policy) What a consent form is for This form documents the patient s agreement to go ahead with the investigation or treatment you have proposed. It is not a legal waiver if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoire to health professionals and patients, by providing a check-list of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way, however, should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient. The law on consent See the Department of Health s Reference guide to consent for examination or treatment for a comprehensive summary of the law on consent (also available at www.doh.gov.uk/consent). Who can give consent Everyone aged 16 or more is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has sufficient understanding and intelligence to enable him or her to understand fully what is proposed, then he or she will have the capacity to give consent for himself or herself. Young people aged 16 and 17, and legally competent younger children, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent for himself or herself, some-one with parental responsibility may do so on their behalf and a separate form is available for this purpose. Even where a child is able to give consent for himself or herself, you should always involve those with parental responsibility in the child s care, unless the child specifically asks you not to do so. If a patient has the mental capacity to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that the patient has given consent orally or non-verbally. When NOT to use this form If the patient is 18 or over and lacks the capacity to give consent, you should use form 4 (form for adults who lack the capacity to consent to investigation or treatment) instead of this form. A patient lacks capacity if they have an impairment of the mind or brain or disturbance affecting the way their mind or brain works and they cannot: understand information about the decision to be made retain that information in their mind use or weigh that information as part of the decision-making process, or communicate their decision (by talking, using sign language or any other means). You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to so under a Lasting Power of Attorney or as a court appointed deputy. Information Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about significant risks which would affect the judgement of a reasonable patient. Significant has not been legally defined, but the GMC requires doctors to tell patients about serious or frequently occurring risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on page 2 of the form or in the patient s notes. References: 1- South East London Cancer Network, Agreed lists of Chemotherapy Regimens http://www.selcn.nhs.uk/portal/index.asp 2- Macmillan Cancer Support, Cancer Information http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/chemotherapy.aspx 3- Royal Marsden NHS Foundation Trust, Consent Forms